Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZAP70 | P43403 | 1/20 | 0.55 |
| ▸ | ALK | Q9UM73 | 9/20 | 0.55 |
| ▸ | INSR | P06213 | 7/20 | 0.55 |
| ▸ | IGF1R | P08069 | 7/20 | 0.55 |
| ▸ | MAP4K1 | Q92918 | 8/20 | 0.51 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13832205 | 0.87 | ALK (0.67) | ZAP70ALKINSRIGF1RMAP4K1 | |
| SCHEMBL13832187 | 0.86 | ALK (0.58) | ALKINSRIGF1RMAP4K1EGFR | |
| SCHEMBL2594892 | 0.81 | ULK1 (0.65) | ZAP70ALKINSRIGF1RMAP4K1 | |
| SCHEMBL13727866 | 0.80 | EGFR (0.67) | ALKINSREGFR | |
| SCHEMBL17792883 | 0.80 | ZAP70 (0.57) | ZAP70ALKINSRIGF1REGFR | |
| SCHEMBL14225903 | 0.79 | ALK (0.58) | ZAP70ALKINSRIGF1RMAP4K1 | |
| SCHEMBL24940958 | 0.77 | ALK (0.71) | ALKINSRIGF1RMAP4K1EGFR | |
| SCHEMBL13832182 | 0.77 | ALK (0.53) | ZAP70ALKINSRIGF1RMAP4K1 | |
| SCHEMBL30631286 | 0.75 | ZAP70 (0.67) | ZAP70ALKINSRIGF1RMAP4K1 | |
| SCHEMBL2589418 | 0.75 | ZAP70 (0.67) | ZAP70ALKINSRIGF1RMAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9834571-B2 | Compounds for inhibiting cell proliferation in EGFR-driven cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-9834518-B2 | Compounds for inhibiting cell proliferation in EGFR-driven cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20160244469-A1 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-25 | — | — | US | disclosed |
| EP-2704572-B1 | COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS | ARIAD PHARMA INC (US) | 2015-12-30 | — | — | EP | disclosed |
| US-20150166591-A1 | METHODS AND COMPOSITIONS FOR RAF KINASE MEDIATED DISEASES | ARIAD PHARMACEUTICALS, INC. | 2015-06-18 | — | — | US | disclosed |
| WO-2013169401-A1 | COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS | ARIAD PHARMACEUTICALS, INC. (US) | 2013-11-14 | — | — | WO | disclosed |
| US-20120316135-A1 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers | ARIAD PHARMACEUTICALS, INC. (US) | 2012-12-13 | — | — | US | disclosed |
| WO-2012151561-A1 | COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS | ARIAD PHARMACEUTICALS, INC. (US) | 2012-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166591-A1 | METHODS AND COMPOSITIONS FOR RAF KINASE MEDIATED DISEASES | BRAF, RAF1, EGFR | ZAP70 547/4885ALK 161/4885INSR 856/4885 |
| US-20120316135-A1 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers | EGFR, MKI67, ERBB2 | ZAP70 2558/4885ALK 293/4885INSR 726/4885 |
| US-20160244469-A1 | Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers | EGFR, MKI67, ERBB2 | ZAP70 2558/4885ALK 293/4885INSR 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.